Consolidated Statement Of Cash Flows

CHUGAI PHARMACEUTICAL CO., LTD. - Filing #7541828

Concept 2023-01-01 to
2023-09-30
As at
2023-09-30
2023-01-01 to
2023-09-30
2023-07-01 to
2023-09-30
2023-01-01 to
2023-09-30
2023-01-01 to
2023-09-30
2023-01-01 to
2023-09-30
2023-01-01 to
2023-09-30
As at
2022-12-31
As at
2022-09-30
2022-07-01 to
2022-09-30
2022-01-01 to
2022-09-30
2022-01-01 to
2022-09-30
2022-01-01 to
2022-09-30
2022-01-01 to
2022-09-30
2022-01-01 to
2022-09-30
2022-01-01 to
2022-09-30
As at
2021-12-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss)
234,266,000,000 JPY
JPY
77,573,000,000 JPY
JPY
234,266,000,000 JPY
234,266,000,000 JPY
JPY
67,797,000,000 JPY
JPY
JPY
271,950,000,000 JPY
271,950,000,000 JPY
271,950,000,000 JPY
JPY
Other
2,711,000,000 JPY
-4,321,000,000 JPY
Subtotal
461,476,000,000 JPY
421,676,000,000 JPY
Income taxes paid
-175,761,000,000 JPY
-151,090,000,000 JPY
Net cash provided by (used in) operating activities
285,715,000,000 JPY
270,585,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-54,150,000,000 JPY
-50,662,000,000 JPY
Proceeds from sale of property, plant and equipment
1,988,000,000 JPY
1,131,000,000 JPY
Purchase of intangible assets
-1,890,000,000 JPY
-8,570,000,000 JPY
Purchase of investment securities
-256,000,000 JPY
-307,000,000 JPY
Proceeds from sale of investment securities
340,000,000 JPY
151,000,000 JPY
Net cash provided by (used in) investing activities
-42,934,000,000 JPY
-123,449,000,000 JPY
Cash flows from financing activities
Proceeds from exercise of employee share options
167,000,000 JPY
229,000,000 JPY
Net cash provided by (used in) financing activities
-137,031,000,000 JPY
-143,286,000,000 JPY
Cash and cash equivalents
331,341,000,000 JPY
222,169,000,000 JPY
274,043,000,000 JPY
267,753,000,000 JPY
Effect of exchange rate changes on cash and cash equivalents
3,422,000,000 JPY
2,441,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.